Introduction: The feasibility, efficacy and safety of maintenance chemotherapy (MCT) after first-line therapy in advanced gastric cancer (AGC) remain obscure. This study aims to explore the efficacy and safety of tegafur-gimeracil-oteracil MCT in stage IV GC. Methods: Seventeen patients with stage IV GC had been involved in this study from the Department of Oncology of Changhai Hospital from January 1st, 2017 to August 31st, 2021. After 6-8 cycles of first-line chemotherapy with SOX (tegafur-gimeracil-oteracil combined with oxaliplatin) or DS (docetaxel combined with tegafur-gimeracil-oteracil) MCT was administered with tegafur-gimeracil-oteracil which continued until disease progression or intolerable adverse effects or death. The PFS, OS, DCR and adverse effects were analyzed. Results: Among 17 patients with stage IV GC, 11 patients received prior SOX-based first-line therapy, 6 patients with TS regimen. The best curative effect of first-line therapy were CR in 1 case, PR in 2 and SD in 14. DCR was 87.5% after tegafur-gimeracil-oteracil MCT, and the median PFS was 13.5 months, the median OS was 23 months. The main adverse effects of tegafur-gimeracil-oteracil MCT were grade 1-3 hematologic and grade 1 fatigue, gastrointestinal symptoms. There were no treatment-related deaths or toxic effects of grade 4.
| Published in | American Journal of Clinical and Experimental Medicine (Volume 9, Issue 5) |
| DOI | 10.11648/j.ajcem.20210905.17 |
| Page(s) | 168-173 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Gastric Cancer, Tegafur-gimeracil-oteracil, Maintenance Chemotherapy
| [1] | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020 Jan; 70 (1): 7-30. |
| [2] | Zhang M, Ding C, Xu L, Ou B, Feng S, Wang G, et al. Comparison of a Tumor-Ratio-Metastasis Staging System and the 8th AJCC TNM Staging System for Gastric Cancer. Frontiers in oncology. 2021; 11: 595421. |
| [3] | Ji XK, Madhurapantula SV, He G, Wang KY, Song CH, Zhang JY, et al. Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility. World journal of gastroenterology. 2021 Jul 28; 27 (28): 4653-66. |
| [4] | Suzuki S, Takahashi A, Ishikawa T, Akazawa K, Katai H, Isobe Y, et al. Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry. Gastric Cancer. 2021 May; 24 (3): 545-66. |
| [5] | Wang Yinkui. The current status of diagnosis and treatment of early gastric cancer in my country: Enlightenment from data from China Gastrointestinal Oncology Surgery Union. Chinese Journal of Gastrointestinal Surgery. 2018; 21 (2). |
| [6] | Pommergaard HC, Nielsen K, Sorbye H, Federspiel B, Tabaksblat EM, Vestermark LW, et al. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. Journal of neuroendocrinology. 2021 May; 33 (5): e12967. |
| [7] | Lui A, Mulder K, Brezden-Masley C, Vickers M, Monzon J, Kennecke H, et al. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Investigational new drugs. 2018 Aug; 36 (4): 674-82. |
| [8] | Solaini L, Ministrini S, Bencivenga M, D'Ignazio A, Marino E, Cipollari C, et al. Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer. 2019 Nov; 22 (6): 1285-93. |
| [9] | Yao Y, Deng R, Liao D, Xie H, Zuo J, Jia Y, et al. Maintenance treatment in advanced HER2-negative gastric cancer. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020 Dec; 22 (12): 2206-12. |
| [10] | Lal R, Dickson J, Cunningham D, Chau I, Norman AR, Ross PJ, et al. A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004 Aug 1; 22 (15): 3023-31. |
| [11] | Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006 Jan 20; 24 (3): 394-400. |
| [12] | Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009 Dec 1; 27 (34): 5727-33. |
| [13] | Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (London, England). 2009 Oct 24; 374 (9699): 1432-40. |
| [14] | Huang H, Jiang Z, Wang T, Zhang S, Bian L, Cao Y, et al. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. Anti-cancer drugs. 2012 Aug; 23 (7): 718-23. |
| [15] | Chen J, Shen W, Xia J, Xu R, Zhu M, Xu M. [Effect of S-1 maintenance chemotherapy following DCF regimen in patients with advanced gastric cancer]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2014 Jun; 34 (7): 1057-60. |
| [16] | Park SR, Kim MJ, Nam BH, Kim CG, Lee JY, Cho SJ, et al. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. European journal of cancer (Oxford, England: 1990). 2017 Sep; 83: 32-42. |
| [17] | Zhang Q, Qian Y, Yin Y. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis. European journal of clinical pharmacology. 2021 Jul 17. |
| [18] | Serizawa A, Kuramochi H, Taniguchi K, Ota M, Katagiri S, Yamada T, et al. Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-3. Medical oncology (Northwood, London, England). 2021 Jul 24; 38 (9): 98. |
APA Style
Kena Zhou, Anjing Zhao, Bin Wang, Jie Li, Yingyi Zhang, et al. (2021). Maintenance Therapy with Tegafur-gimeracil-oteracil After First-line Chemotherapy in Stage IV Gastric Cancer: A Retrospective Study. American Journal of Clinical and Experimental Medicine, 9(5), 168-173. https://doi.org/10.11648/j.ajcem.20210905.17
ACS Style
Kena Zhou; Anjing Zhao; Bin Wang; Jie Li; Yingyi Zhang, et al. Maintenance Therapy with Tegafur-gimeracil-oteracil After First-line Chemotherapy in Stage IV Gastric Cancer: A Retrospective Study. Am. J. Clin. Exp. Med. 2021, 9(5), 168-173. doi: 10.11648/j.ajcem.20210905.17
AMA Style
Kena Zhou, Anjing Zhao, Bin Wang, Jie Li, Yingyi Zhang, et al. Maintenance Therapy with Tegafur-gimeracil-oteracil After First-line Chemotherapy in Stage IV Gastric Cancer: A Retrospective Study. Am J Clin Exp Med. 2021;9(5):168-173. doi: 10.11648/j.ajcem.20210905.17
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajcem.20210905.17,
author = {Kena Zhou and Anjing Zhao and Bin Wang and Jie Li and Yingyi Zhang and Meihong Wu and Xianbao Zhan},
title = {Maintenance Therapy with Tegafur-gimeracil-oteracil After First-line Chemotherapy in Stage IV Gastric Cancer: A Retrospective Study},
journal = {American Journal of Clinical and Experimental Medicine},
volume = {9},
number = {5},
pages = {168-173},
doi = {10.11648/j.ajcem.20210905.17},
url = {https://doi.org/10.11648/j.ajcem.20210905.17},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20210905.17},
abstract = {Introduction: The feasibility, efficacy and safety of maintenance chemotherapy (MCT) after first-line therapy in advanced gastric cancer (AGC) remain obscure. This study aims to explore the efficacy and safety of tegafur-gimeracil-oteracil MCT in stage IV GC. Methods: Seventeen patients with stage IV GC had been involved in this study from the Department of Oncology of Changhai Hospital from January 1st, 2017 to August 31st, 2021. After 6-8 cycles of first-line chemotherapy with SOX (tegafur-gimeracil-oteracil combined with oxaliplatin) or DS (docetaxel combined with tegafur-gimeracil-oteracil) MCT was administered with tegafur-gimeracil-oteracil which continued until disease progression or intolerable adverse effects or death. The PFS, OS, DCR and adverse effects were analyzed. Results: Among 17 patients with stage IV GC, 11 patients received prior SOX-based first-line therapy, 6 patients with TS regimen. The best curative effect of first-line therapy were CR in 1 case, PR in 2 and SD in 14. DCR was 87.5% after tegafur-gimeracil-oteracil MCT, and the median PFS was 13.5 months, the median OS was 23 months. The main adverse effects of tegafur-gimeracil-oteracil MCT were grade 1-3 hematologic and grade 1 fatigue, gastrointestinal symptoms. There were no treatment-related deaths or toxic effects of grade 4.},
year = {2021}
}
TY - JOUR T1 - Maintenance Therapy with Tegafur-gimeracil-oteracil After First-line Chemotherapy in Stage IV Gastric Cancer: A Retrospective Study AU - Kena Zhou AU - Anjing Zhao AU - Bin Wang AU - Jie Li AU - Yingyi Zhang AU - Meihong Wu AU - Xianbao Zhan Y1 - 2021/10/19 PY - 2021 N1 - https://doi.org/10.11648/j.ajcem.20210905.17 DO - 10.11648/j.ajcem.20210905.17 T2 - American Journal of Clinical and Experimental Medicine JF - American Journal of Clinical and Experimental Medicine JO - American Journal of Clinical and Experimental Medicine SP - 168 EP - 173 PB - Science Publishing Group SN - 2330-8133 UR - https://doi.org/10.11648/j.ajcem.20210905.17 AB - Introduction: The feasibility, efficacy and safety of maintenance chemotherapy (MCT) after first-line therapy in advanced gastric cancer (AGC) remain obscure. This study aims to explore the efficacy and safety of tegafur-gimeracil-oteracil MCT in stage IV GC. Methods: Seventeen patients with stage IV GC had been involved in this study from the Department of Oncology of Changhai Hospital from January 1st, 2017 to August 31st, 2021. After 6-8 cycles of first-line chemotherapy with SOX (tegafur-gimeracil-oteracil combined with oxaliplatin) or DS (docetaxel combined with tegafur-gimeracil-oteracil) MCT was administered with tegafur-gimeracil-oteracil which continued until disease progression or intolerable adverse effects or death. The PFS, OS, DCR and adverse effects were analyzed. Results: Among 17 patients with stage IV GC, 11 patients received prior SOX-based first-line therapy, 6 patients with TS regimen. The best curative effect of first-line therapy were CR in 1 case, PR in 2 and SD in 14. DCR was 87.5% after tegafur-gimeracil-oteracil MCT, and the median PFS was 13.5 months, the median OS was 23 months. The main adverse effects of tegafur-gimeracil-oteracil MCT were grade 1-3 hematologic and grade 1 fatigue, gastrointestinal symptoms. There were no treatment-related deaths or toxic effects of grade 4. VL - 9 IS - 5 ER -
Information
Email: